Tharimmune, Inc. | WebDisclosure

PRESS RELEASE

published on 05/19/2025 at 14:01, 11 months 24 days ago

Tharimmune Appoints Renowned Counter-Terrorism and Critical Infrastructure Expert James Gordon Liddy (CDR US Navy SEAL (Ret)) as Key Strategic Advisor Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback
Tharimmune, Inc. appoints James Gordon Liddy as strategic advisor for TH104 development, targeting high-potency opioid exposure. FDA feedback positive for prophylaxis indication

Tharimmune Inc. FDA Feedback High-Potency Opioids James Gordon Liddy TH104 Development
BRIEF

published on 05/06/2025 at 14:06, 1 year ago

Tharimmune Reports Positive Phase 1 Results for TH104

Tharimmune Inc. FDA Feedback Phase 1 Study Opioid Prophylaxis TH104 Buccal Film
BRIEF

published on 05/06/2025 at 14:06, 1 year ago

Tharimmune annonce des résultats positifs de phase 1 pour le TH104

Tharimmune Inc. Étude De Phase 1 Commentaires De La FDA Prophylaxie Aux Opioïdes Film Buccal TH104
PRESS RELEASE

published on 05/06/2025 at 14:01, 1 year ago

Tharimmune Presents Positive Clinical Data Highlighting TH104 Metabolic Profile and Advances Program for Prophylaxis Against Ultrapotent Opioid Exposure Following FDA Feedback
Tharimmune, Inc. presents promising pharmacokinetic and metabolism data of TH104, a buccal film of nalmefene, for prophylaxis against opioid exposure. Study results showcased at Digestive Disease Week 2025

Tharimmune Inc. TH104 Buccal Film Pharmacokinetic Study Opioid Prophylaxis
BRIEF

published on 05/01/2025 at 14:06, 1 year ago

Le TH104 de Tharimmune sera présenté lors de conférences médicales importantes

Biopharmaceutique TH104 Tharimmune DDW 2025 EASL 2025
BRIEF

published on 05/01/2025 at 14:06, 1 year ago

Tharimmune's TH104 to Be Presented at Notable Medical Conferences

TH104 Biopharmaceutical Tharimmune DDW 2025 EASL 2025
PRESS RELEASE

published on 05/01/2025 at 14:01, 1 year ago

Tharimmune Abstracts Accepted for Presentation at Upcoming DDW and EASL Conferences
Tharimmune, Inc. announces presentation of clinical data on lead drug TH104 at DDW and EASL Annual Meetings in May 2025, addressing unmet medical needs in immunology & inflammation

Tharimmune Inc. TH104 Clinical Data Immunology Unmet Medical Needs
BRIEF

published on 04/30/2025 at 14:06, 1 year ago

Tharimmune élargit son conseil d'administration avec de nouvelles nominations

Stratégie De Croissance Biopharmaceutique Direction Nominations Au Conseil D'administration Tharimmune
BRIEF

published on 04/30/2025 at 14:06, 1 year ago

Tharimmune Expands Board with New Appointments

Growth Strategy Biopharmaceutical Leadership Board Appointments Tharimmune
PRESS RELEASE

published on 04/30/2025 at 14:01, 1 year ago

Tharimmune Appoints Clay Kahler and Gary Stetz to its Board of Directors
Tharimmune, Inc. appoints Clay Kahler and Gary Stetz to its Board of Directors, expanding to 9 members. Kahler brings life sciences expertise while Stetz contributes financial acumen

Board Of Directors Financial Expertise Tharimmune Clay Kahler Gary Stetz

Published on 05/13/2026 at 03:30, 20 minutes ago

Torq Resources Grants Stock Options
Published on 05/13/2026 at 00:00, 3 hours 50 minutes ago

Onco-Innovations Announces Initiation of Research Collaboration within PROmAI
Published on 05/12/2026 at 23:35, 4 hours 15 minutes ago

Infield Minerals Closes $1.25 Million Financing
Published on 05/12/2026 at 21:55, 5 hours 55 minutes ago

UraniumX Discovery Corp Announces Option Agreement with Gold'n Futures
Published on 05/12/2026 at 21:42, 6 hours 8 minutes ago

Kidoz Inc. to Present at Planet MicroCap Las Vegas 2026

View all ACCESSWIRE

Published on 05/12/2026 at 23:47, 4 hours 2 minutes ago

Nebius welcomes Clarifai’s core team and licenses inference IP to strengthen Nebius Token Factory
Published on 05/12/2026 at 22:25, 5 hours 24 minutes ago

Evotec SE Successfully Placed €116.1 Million Convertible Bonds
Published on 05/12/2026 at 20:21, 7 hours 28 minutes ago

Nebius breaks ground on gigawatt-scale AI factory in Independence, Missouri
Published on 05/12/2026 at 19:35, 8 hours 14 minutes ago

AUSTRIACARD HOLDINGS AG: Q1 2026 Financial Results
Published on 05/12/2026 at 19:35, 8 hours 15 minutes ago

2026 Annual General Meeting: Strong vote by shareholders in favour of continuity in leadership and strategy

View all EQS

Published on 05/12/2026 at 18:15, 9 hours 35 minutes ago

AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 30/04/2026
Published on 05/12/2026 at 18:15, 9 hours 35 minutes ago

AXA: Information relating to the number of voting rights and shares making up the share capital on 30/04/2026
Published on 05/12/2026 at 18:10, 9 hours 40 minutes ago

imerys-12-05-2026-communiqué-compte-rendu-de-l-assemblée-générale-ordinaire-du-12-mai-2026
Published on 05/12/2026 at 18:10, 9 hours 40 minutes ago

imerys-12-05-2026-press-release-summary-of-the-ordinary-shareholders-general-meeting-12-may-2026
Published on 05/12/2026 at 17:50, 10 hours ago

Damartex fait évoluer sa gouvernance et engage une réflexion stratégique autour de ses activités

View all LES ECHOS COMFI WIRE

News